DBV skin-based peanut allergy therapy reports 68% three-year tolerance
DBV said a skin-based therapy for pediatric peanut allergy showed strong safety and convenience, with 68% of young children tolerating peanuts after three years, and it is pursuing regulatory progress.
A novel skin-based therapy for pediatric peanut allergy showed strong safety, convenience and long-term efficacy, with 68% of young children tolerating peanuts after three years. Regulatory progress is advancing, and the THRIVE study is designed to confirm lifelong benefits and improved quality of life.